Viral Vectors and Plasmid DNA Manufacturing Market Research Report—Global Forecast till 2027

Viral Vectors and Plasmid DNA Manufacturing Market Research Report: Information by Vector Type (Plasmid DNA, Viral Vector, Non-viral Vector), by Disease Type(Cancer, Genetic Disorder, and Infectious Disease), by Applications (Antisense & RNAi Therapy,Gene Therapy,Cell Therapy, Vaccinology, and Research), by Workflow (Upstream Processing and Downstream Processing), by End User (Pharmaceutical and Biopharmaceutical Companies, and Research Institutes) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2027

ID: MRFR/HC/9195-HCR | September 2021 | Region: Global | 120 pages

Viral Vectors and Plasmid DNA Manufacturing  Market Overview


The global viral vectors and plasmid DNA manufacturing market is expected to cross  ~USD 587.5 million in 2027 at a CAGR of ~16.92% during the forecast period.

Viral vectors are tools meant to transport genetic material into cells and have become a method for gene transfer due to high transfection efficiency, efficient gene delivery, and stable gene expression. Plasmid DNA also plays a major role in the healthcare industry, as it is used as a therapeutic agent in gene directly therapy orvaccine antigens generation. It is also used as a master-template product to support the production of new and emerging biopharmaceutical products and processes, including RNA and cell therapies and in-vitro protein production.

Recent technological advancements and the emergence of several other innovative viral and non-viral gene delivery methods being utilized for the development of various therapiesare acting as a major boosting factor for the market growth.  Viruses progress to advance particular mechanisms and transport their genomes inside the cells they contaminate. Several  types of viral vectors are being used to deliver nucleic acids into the genetic makeup of cells, such as adeno-associated virus, retrovirus, lentivirus, adenovirus, and herpes simplex virus.  Each virus has its own benefits and drawbacks for specific applications. In addition, increasing R&D on cancer research owing to the rising burden of chronicdiseases and the increasing demand for DNA the rapeutics are some of the key factors contributing to the growth of viral vectors and plasmid DNA manufacturing market.

COVID-19 Analysis

The rising prevalence of COVID-19 is projected to influence market growth over the forecast period.  As the coronavirus outbreak continues, the majority of the healthcare companies experienced a significant loss, there by hampering the viral vectors and plasmid DNA manufacturing market. The emergence of the COVID-19 pandemic has plummeted the global economy, severely impacting production and demand across numerous verticals and disrupting the supply chain.

The viral vector and plasmid DNA manufacturing market has showcased a positive impact due to the ongoing COVID-19 spread.  The pandemic has created lucrative opportunities for the industry players of viral vectors and plasmid DNA manufacturing market.  For example, in December 2020 and February 2021, AstraZeneca (UK) and Janssen Pharmaceuticals (Belgium) companies developed the COVID-19 viral vector-based vaccine (AZD1222)vaccine.  The innovation of these vaccines by major market players hasacceleratedthe demand for viral vectors, thereby increasing revenue for viral vector manufacturers.

Market Drivers



  • Rising prevalence of genetic disorders and infectious diseases



There has been a surge in the prevalence rate of genetic and infectious diseases inthe past years. According to an article published in the National Institutes of Health (NIH), sickle cell anemia affectedan estimated 100,000 people in the US in 2019. The rising application of gene therapy for the treatment of viral infections such as adeno-associated viruses, poxviruses, herpes simplex viruses, and retroviruses is anticipated to boost the adoption of gene therapies which in turn aids to propel themarket growth of the viral vectors and plasmid DNA manufacturing in the near future.



  • Increasing number of market players involved in new product launch, strategic collaborations, acquisition, and geography expansion



GE Healthcare Life Sciences (US) and Children’s Medical Research Institute (Australia)entered into a collaboration for the development of new affinity ligands for the purification of adeno-associated viral select AAV) vectors used in gene therapies. The collaborationwas focused on multiple AAV types enhancing the chromatographic separation of AAV-based vectors. Thus, such collaborations are anticipated to improve the manufacturing efficiency and scalability of gene the rapies, enabling the availability of viral vectors on a global scale and opening lucrative opportunities in the market.

Furthermore, market players are also engaged in leveraging external capital to advance their business operations.  For instance, in April 2021, Albumedix (UK)collaborated with Cobra Biologics (US) for the upstream and downstream processing of AAV and lentiviral vector. The collaboration is intended for stability enhancement and process optimization.

Market Restraints



  • Challenges in viral vector manufacturing capacities



Manufacturers of viral vector and plasmid DNA whose products are in phase III of clinical trials and commercial production of viral vectors are facing numerous challenges. These challenges includethe unsuitability of many existing vector production technologies with respect to productivity, efficiency, stability, etc. In addition, there is also a necessity for both large and small-volume manufacturing companies in the market to carry out various research activities.

Market Opportunities



  • Increasing employment of viral vectors and plasmid DNA for the R&D of advanced therapies



Viral vectors and plasmid DNA are being used widely for developing gene therapies which is one of the growing areas in advanced therapies. Healthcare companies are involved in innovating  DNA vectors for the production of vaccines.  For instance, in 2021, Touchlight (UK) developed a scalable, rapid, easy-to-transfer, cell-free method to make unique DNA vectors, known as Doggybone DNA (dbDNA). The Touchlight’sdb DNA can be constructed ata multi-gram scale within five days. The company is also investing in growing the number of proof-of-concept studies in animals for DNA-based the rapies, which is also a propelling factor for the market growth.

Technology Analysis

The increase in research activities for the advancement of viral vectors and plasmid DNA and increased use of these vectors in the development of treatments for various diseases such as cancer and sickle cell anemia will significantly contribute to market growth.  For instance, in October 2019, a group of researchers at the National Institutes of Health (NIH) developed a new, improved viral vector for sickle cell anemia treatment. The new viral vector is tentimes efficient than already existing viral vectors based on the hypothesis of researchers. In addition, major market players are also fueling the market growth for viral vector and plasmid DNA manufacturing by new product launches, mergers&acquisitions, and strategic collaborations amongst each other.  For instance, in May 2019, Thermo Fisher Scientific (US) introduced Mag MAX Viral/Pathogen kits and reagents, which use magnetic bead-based technology to purify high-quality nucleic acid from a range of research samples, both manually and through automation. Such innovation by the established companies is anticipated to boost the market growth for viral vectors and plasmid DNA manufacturing.

Segment Overview


Based on the viral vector typeof the global viral vectors and plasmid DNA manufacturing market, the market is segmented into plasmid DNA, viral vectors, and non-viral vectors.


By Type



  • Plasmid DNA


Plasmid DNA is used as a master template to support the production of new and emerging biopharmaceutical products and processes, including RNA &cell therapies and in-vitro protein production. The recent advancements in plasmid DNA have led to the emergence of several other innovative viral and non-viral gene delivery approaches that are used for the development of various the rapies that require gene modification. The major factors helping the market groware the rising preference for plasmid DNA in gene transfer and it susage as a vector in gene therapy and vaccinology. Plasmid DNA is also used as raw material in the production of various viral vectors,further attributing to this segment's market growth.



  • Viral Vector


The viral vectors segment accounted for a major share in 2020. Viral vectors were widely used to develop vaccinesduring the COVID-19 pandemic due to the widespread urgency to contain the spread of this disease globally. High transfection efficiency, effective gene delivery, and stable gene expression have enabledviral vectors a preferred choice for gene transfer which in turn is propelling the market growth.



  • Non-Viral Vector


Non-replicating viral vectors are used in the COVID-19 viral vector vaccines. Increasing adoption of these non-viral vectors for vaccine development in the pandemic further boosts the market growth. According to an article published in PubMed in 2017, the development of non-viral DNA vectors has progressed steadily, especially in plasmid vector length reduction. This factor is also significantly contributing to the market growth of the segment.


By Workflow Type



  • Upstream Processing


Upstream processing includes virus cells, cell culture, and cell recovery. The companies’ shifting focus on offering a broad range of advanced products and services for upstream processingactsas an accelerating factor for the market growth. For instance, Boehringer Ingelheim is involved in offering a high titer plasmid DNA fermentation process that produces high yield plasmid DNA in E. coli biomass. Similarly, GE Healthcare is involved in the development of upstream cell culture processes using modern tools and technologies.



  • Downstream Processing


The downstream processing segment dominated the viral vectors andplasmid DNA manufacturing market. Downstream processing is focused on eradicating contaminants originating from host cells or culture media. The process further produces large volumes of concentrated, biologically active viruses that are highly efficient in gene transfer.


By Application



  • Antisense & RNAi Therapy


According to the article published in 2020 in Viruses, RNA interference (RNAi) is being used as an alternative antiviral therapy. RNAi delivery in the form of short interfering RNA (siRNA), short hairpin RNA (shRNA), and micro-RNA (miRNA) have proven efficacy in gene silencing for therapeutic applications against viral diseases. This factor is propelling the market growth of the segment.



  • Gene Therapy


Gene therapies in manufacturingviral vectors are widely recommended for various disorders such as sickle cell anemia, cystic fibrosis, hemophilia, Duchenne muscular dystrophy, severe combined immunodeficiency, Parkinson’s diseases, etc.The increasing prevalence of genetic disorders, growing awareness of gene therapy, and infectious diseases globally are likely to upsurge the market growth of gene therapy in the viral vector and plasmid DNA manufacturing market.



  •  Cell Therapy


The increasing number of companies involved in manufacturing approaches for producing the cell therapies, and to a large degree for viral vector manufacturing processes to meet the clinical requirements for late-phase clinical trials for viral vectors and plasmid DNA is driving the market growth for this segment.



  • Vaccinology


The vaccinology segment dominated the viral vectors and plasmid DNA manufacturing market in 2020. This can be attributed to the rising use of viral vectors in vaccine development owing to their high efficiency-related benefits such as the potential to elicit a wide immune response, easy manufacturing, and safety profiles.



  •  Research


Increasing R&D activities focused on viral vectors and plasmid DNA manufacturing along with rising R&D spending by governments globally are fueling the market growth of this segment.


By Disease Type



  • Cancer


Based on application, cancer dominated the global viral vectors and plasmid DNA manufacturing market in 2020. The growth of this segment can be attributed to viruses that have proven to beefficient as an ideal vector for gene therapy production against severalcancer types. According to the published article in Frontiers in April 2020, the tumor immunotherapy approaches, such as immune checkpoint blockade (ICB) and chimeric antigen receptor T-cell (CAR-T) therapy, have been successful in cancer treatment and has also revolutionized cancer treatment by improving efficacy and extending treatment to a larger proportion of cancer patients.



  • Genetic Disorders


Gene therapies along with viral vectors are widely recommended for a range of genetic disorders, such as severe combined immunodeficiency, sickle cell anemia, cystic fibrosis, Duchenne muscular dystrophy, hemophilia, Parkinson’s disease, and Gaucher disease, among others. Genetic disorders are one of the most focused application segmentsfor gene therapy. The increasing number of genetic disorders and market players involved in the development of viral vectors are acting as a stimulating factor for market growth. For instance, according to the data published in Science Direct in 2020, an incidence of 3.8 per 1,000 chromosomal disorders, 646.4 per 1,000 multifactorial disorders,and 20 per 1,000 single-gene disorders occur every year.



  • Infectious Diseases


Viral vector-based vaccines are being used widely to fight major diseases, such as HIV-1 and malaria. According to the article published in 2019, HIV/AIDS continues to be a global burden andhas devastating health effects globally, with over 39 million HIV/AIDS-related deaths withmore than 36 million people currently living with HIV. With this rising burden of infectious diseases, there is a need for viral vectors and the manufacturing of plasmid DNA.



  • Others


The other applications of viral vector and plasmid DNA manufacturing include metabolic disorders and heart defects. Increasing adoption of viral vectors for the treatment of metabolic disorders and heart defectsis driving the market growth of this segment. Gene therapy has proved to be an effective treatment for various metabolic disorders caused by genetic defects in both animal models and human clinical trials. These therapies are being used as a viral-mediated gene addition approach which is another key factor boosting the market growth of viral vectors and plasmid DNA manufacturing.


By End user



  • Pharmaceutical and Biopharmaceutical Companies


The increasing number of gene therapy-based R&D programs by many pharmaceuticals and biopharmaceutical companies are triggering the market growth of viral vectors and plasmid DNA manufacturing.



  •  Research Institutes


The research institutes segment dominated the viral vectors and plasmid DNA manufacturing market in 2020. The rising number of research institutes is expected to increase the demand for viral vectors in the global market. National Institute for Physiological Sciences (Japan), Maine Medical Center Research Institute (US), and the Viral Vector Core (VVC) (Belgium)are few research communitiesinvolved in the production of vectors.


By Region



  • North America


North America dominated the market for global viral vectors and plasmid DNA manufacturin gowing to the presence of a large number of research centers involved in the R&D of advanced therapies. In addition, the construction of the manufacturing plants by the players of other regions in North Americais another propelling factor for the market growth of this region. For instance, in February 2021, Vibalogics (Germany)builta virotherapy manufacturing plant in Massachusetts. The company also expanded its manufacturing capabilities with aninvestment of USD 150 million.



  • Asia-Pacific


Asia-Pacific is projected to witness rapid growth in the global viral vectors and plasmid DNA manufacturing market. The market in the Asia-Pacific region has gained momentum in terms of product approvals and pipeline programs pertaining to viral vectors and plasmid DNA manufacturing. This can be attributed to the establishment of accelerated approval pathways, the rising pool of patient population, growing private and government investments, and increasing healthcare needs. Furthermore, the unmet needs in the personalized medicine arena are leading to the increasing demand for viral vector supply.


Competitive Landscape


The viral vectors and plasmid DNA manufacturing market is profitable, both for existing players as well as new entrants. A substantial level ofrivalry is witnessed among the market players in the viral vector and plasmid DNA manufacturing market. Based on MRFR’sanalysis, market players have adopted different strategies, innovative research activities, product approvals, and development techniques to expand their business and secure their position in the global viral vectors and plasmid DNA manufacturingmarket.


Key Players



  • Cognate BioServices, Inc. (US)  

  • Catalent Pharma Solutions (US)

  • Fujifilm Holdings Corporation (Japan)

  • Johnson & Johnson (US)

  • Sanofi Corporation (France)

  • Hoffmann-LA Roche Ltd (Switzerland)

  • 4D Molecular Therapeutics (US)

  • Sirion Biotech GmbH (Germany)

  • Voyager Therapeutics (US)

  • Thermo Fisher Scientific, Inc. (US)

  • Gene Therapy Catapult (UK)

  • UniQure(Netherlands)

  • MassBiologics (US)

  • Renova Therapeutics (US)

  • Shenzhen SiBionoGeneTech Co., Ltd (China)


Recent Developments



  • In January 2020, Genopis Inc. (US) announced that it wouldbuild a contract manufacturing business for plasmid DNA production in the United States with its South Korea-based partner Helixmith (South Korea).

  • In April 2018, GE Healthcare (US) created a ‘factory-in-a-box’ facility for the production of viral vector-based drugs, including viral vector vaccines, oncolytic viruses, and gene and cell therapies.


Report Overview:

The study covers the existing short-term and long-term market effects, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market. Scope of the Report The scope of the global viral vectors and plasmid DNA manufacturingmarket study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on product type, application, and region.


Market Segmentation


Global Viral Vectors and Plasmid DNA Manufacturing, by Vector Type



  • Plasmid DNA

  • Viral Vector

  • Non-Viral Vector


Global Viral Vectors and Plasmid DNA Manufacturing, by Workflow Type



  • Upstream Processing

  •  Downstream Processing


Global Viral Vectors and Plasmid DNA Manufacturing, by Disease Type



  • Cancer

  • Genetic Disorders

  • Infectious Diseases

  • Others


Global Viral Vectors and Plasmid DNA Manufacturing, by Application



  • Antisense & RNAi Therapy

  •  Gene Therapy

  •  Cell Therapy

  •  Vaccinology

  •  Research


Global Viral Vectors and Plasmid DNA Manufacturing, by End User



  • Pharmaceutical and Biopharmaceutical Companies

  • Research Institutes


Global Viral Vectors and Plasmid DNA Manufacturing, by Region



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    •  Japan

    •  India

    •  Australia

    •  South Korea

    •  Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America





Report Scope:
Report Attribute/Metric Details
  Market Size   2027: ~USD 587.5million
  CAGR   ~16.92%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2018 & 2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Vector Type, Workflow, Disease Type,Application and End user
  Geographies Covered   North America, Europe, Asia-Pacific, Rest of the World
  Key Vendors   Cognate BioServices, Inc. (US) Catalent Pharma Solutions (US) Fujifilm Holdings Corporation (Japan) Johnson & Johnson (US) Sanofi Corporation (France) F. Hoffmann-LA Roche Ltd (Switzerland) 4D Molecular Therapeutics (US) Sirion Biotech GmbH (Germany) Voyager Therapeutics (US) Thermo Fisher Scientific, Inc. (US) Gene Therapy Catapult (UK) UniQure (Netherlands) MassBiologics (US) Renova Therapeutics (US) Shenzhen SiBionoGeneTech Co., Ltd (China)
  Key Market Opportunities   Increasing employment of viral vectors and plasmid DNA for the R&D of advanced therapies
  Key Market Drivers   Rising prevalence of genetic disorders and infectious diseases Increasing number of market players involved in new product launch, strategic collaborations, acquisition, and geography expansion


TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Demand and Supply

5.3.3. Regional Impact

5.3.4. Impact on R&D

6. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET, BY VECTOR TYPE

6.1. Overview

6.2. Plasmid DNA

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.3. Viral Vector

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

6.4. Non-Viral Vector

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE

7.1. Overview

7.2. Upstream Processing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

7.3. Downstream Processing

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION

8.1. Overview

8.2. Antisense & RNAi Therapy

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.3. Gene Therapy

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.4. Cell Therapy

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.5. Vaccinology

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

8.6. Research

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE

9.1. Overview

9.2. Cancer

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9.3. Genetic Disorders

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9.4. Infectious Diseases

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

9.5. Others

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

10. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER

10.1. Overview

10.2. Pharmaceutical and Biopharmaceutical Companies

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

10.3. Research Institutes

Market Estimates & Forecast, by Region, 2018–2027

Market Estimates & Forecast, by Country, 2018–2027

11. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET, BY REGION

11.1. Overview

11.2. North America

11.2.1. US

11.2.2. Canada

11.3. Europe

11.3.1. Germany

11.3.2. France

11.3.3. Italy

11.3.4. Spain

11.3.5. UK

11.3.6. Rest of Europe

11.4. Asia-Pacific

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. Australia

11.4.5. South Korea

11.4.6. Rest of Asia-Pacific

11.5. Rest of the World

11.5.1. Middle East

11.5.2. Africa

11.5.3. Latin America

12. COMPANY LANDSCAPE

12.1. Overview

12.2. Competitive Analysis

12.3. Market Share Analysis

12.4. Major Growth Strategy in the Global Viral Vectors And Plasmid DNA ManufacturingMarket

12.5. Competitive Benchmarking

12.6. Leading Players in Terms of Number of Developments in the Global Viral Vectors And Plasmid Dna ManufacturingMarket

12.7. Key developments and Growth Strategies

12.7.1. New Product Launch/Service Deployment

12.7.2. Merger &Acquisitions

12.7.3. Joint Ventures

12.8. Major Players Financial Matrix

12.8.1. Sales & Operating Inc.ome, 2020

12.8.2. Major Players R&D Expenditure, 2020

13. COMPANY PROFILES

13.1. Cognate BioservicesInc.

13.1.1. Company Overview

13.1.2. Products Offered

13.1.3. Financial Overview

13.1.4. Key Developments

13.1.5. SWOT Analysis

13.1.6. Key Strategies

13.2. Catalent Pharma Solutions

13.2.1. Company Overview

13.2.2. Products Offered

13.2.3. Financial Overview

13.2.4. Key Developments

13.2.5. SWOT Analysis

13.2.6. Key Strategies

13.3. Fujifilm Holdings Corporation

13.3.1. Company Overview

13.3.2. Products Offered

13.3.3. Financial Overview

13.3.4. Key Developments

13.3.5. SWOT Analysis

13.3.6. Key Strategies

13.4. Johnson & Johnson

13.4.1. Company Overview

13.4.2. Products Offered

13.4.3. Financial Overview

13.4.4. Key Developments

13.4.5. SWOT Analysis

13.4.6. Key Strategies

13.5. Sanofi Corporation

13.5.1. Company Overview

13.5.2. Products Offered

13.5.3. Financial Overview

13.5.4. Key Developments

13.5.5. SWOT Analysis

13.5.6. Key Strategies

13.6. F-Hoffman LA Roche Ltd

13.6.1. Company Overview

13.6.2. Products Offered

13.6.3. Financial Overview

13.6.4. Key Developments

13.6.5. SWOT Analysis

13.6.6. Key Strategies

13.7. 4D Molecular Therapeutics

13.7.1. Company Overview

13.7.2. Products Offered

13.7.3. Financial Overview

13.7.4. Key Developments

13.7.5. SWOT Analysis

13.7.6. Key Strategies

13.8. Sirion Biotech GmbH

13.8.1. Company Overview

13.8.2. Products Offered

13.8.3. Financial Overview

13.8.4. Key Developments

13.8.5. SWOT Analysis

13.8.6. Key Strategies

13.9. Voyager Therapeutics

13.9.1. Company Overview

13.9.2. Products Offered

13.9.3. Financial Overview

13.9.4. Key Developments

13.9.5. SWOT Analysis

13.9.6. Key Strategies

13.10. Thermo Fisher Scientific

13.10.1. Company Overview

13.10.2. Products Offered

13.10.3. Financial Overview

13.10.4. Key Developments

13.10.5. SWOT Analysis

13.10.6. Key Strategies

13.11. Gene Therapy Catapult

13.11.1. Company Overview

13.11.2. Products Offered

13.11.3. Financial Overview

13.11.4. Key Developments

13.11.5. SWOT Analysis

13.11.6. Key Strategies

13.12. Uniqure

13.12.1. Company Overview

13.12.2. Products Offered

13.12.3. Financial Overview

13.12.4. Key Developments

13.12.5. SWOT Analysis

13.12.6. Key Strategies

13.13. Mass Biologics

13.13.1. Company Overview

13.13.2. Products Offered

13.13.3. Financial Overview

13.13.4. Key Developments

13.13.5. SWOT Analysis

13.13.6. Key Strategies

13.14. Renova Therapeutics

13.14.1. Company Overview

13.14.2. Products Offered

13.14.3. Financial Overview

13.14.4. Key Developments

13.14.5. SWOT Analysis

13.14.6. Key Strategies

13.15. Shenzhen SiBionoGeneTech Co., Ltd

13.15.1. Company Overview

13.15.2. Products Offered

13.15.3. Financial Overview

13.15.4. Key Developments

13.15.5. SWOT Analysis

13.15.6. Key Strategies

14. APPENDIX

14.1. References

14.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET SYNOPSIS, 2018–2027

TABLE 2 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET ESTIMATES &FORECAST, 2018–2027(USD MILLION)

TABLE 3 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET, BYVECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 4 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 5 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 6 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 7 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 8 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 9 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 10 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 11 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 12 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 13 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 14 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 15 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 16 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 17 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 18 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 19 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 20 CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 21 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 22 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 23 EUROPE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 24 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 25 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 26 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 27 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 28 GERMANY: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 29 GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 30 GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 31 GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 32 GERMANYVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 33 UK: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 34 UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 35 UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 36 UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 37 UKVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 38 FRANCE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 39 FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 40 FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 41 FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 42 FRANCEVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 43 ITALY: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 44 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 45 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 46 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 47 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 48 SPAIN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 49 SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 50 SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 51 SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 52 SPAINVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 53 REST OF EUROPE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 54 REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 55 REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 56 REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 57 REST OF EUROPEVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 58 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 59 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 60 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 61 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 62 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 63 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 64 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 65 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 66 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 67 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 68 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 69 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 70 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 71 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 72 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 73 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 74 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 75 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 76 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 77 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 78 SOUTH KOREAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 79 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 80 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 81 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 82 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 83 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 84 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 85 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 86 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 87 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 88 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 89 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 90 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 91 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 92 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 93 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 94 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 95 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 96 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 97 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 98 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 99 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 100 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 101 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER TYPE, 2018–2027 (USD MILLION)

TABLE 102 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 103 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 104 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 105 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 106 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 107 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 108 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 109 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 110 AFRICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 111 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

TABLE 112 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018–2027 (USD MILLION)

TABLE 113 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018–2027 (USD MILLION)

TABLE 114 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018–2027 (USD MILLION)

TABLE 115 LATIN AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018–2027 (USD MILLION)

TABLE 116 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018–2027 (USD MILLION

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET

FIGURE 4 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET SHARE, BY VECTOR TYPE, 2020 (%)

FIGURE 5 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY APPLICATION, 2020 (%)

FIGURE 6 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 NORTH AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 EUROPE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 12 COGNATE BIOSERVICES, INC.: KEY FINANCIALS

FIGURE 13 COGNATE BIOSERVICES, INC.: SEGMENTAL REVENUE

FIGURE 14 COGNATE BIOSERVICES, INC.: REGIONAL REVENUE

FIGURE 15 CATALENT PHARMA SOLUTIONS: KEY FINANCIALS

FIGURE 16 CATALENT PHARMA SOLUTIONS: SEGMENTAL REVENUE

FIGURE 17 CATALENT PHARMA SOLUTIONS: REGIONAL REVENUE

FIGURE 18 FUJIFILM HOLDINGS CORPORATION: KEY FINANCIALS

FIGURE 19 FUJIFILM HOLDINGS CORPORATION: SEGMENTAL REVENUE

FIGURE 20 FUJIFILM HOLDINGS CORPORATION: REGIONAL REVENUE

FIGURE 21 JOHNSON & JOHNSON: KEY FINANCIALS

FIGURE 22 JOHNSON & JOHNSON: SEGMENTAL REVENUE

FIGURE 23 JOHNSON & JOHNSON: REGIONAL REVENUE

FIGURE 24 SANOFI CORPORATION: KEY FINANCIALS

FIGURE 25 SANOFI CORPORATION: SEGMENTAL REVENUE

FIGURE 26 SANOFI CORPORATION: REGIONAL REVENUE

FIGURE 27 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 28 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 29 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 30 4D MOLECULAR THERAPEUTICS: KEY FINANCIALS

FIGURE 31 4D MOLECULAR THERAPEUTICS: SEGMENTAL REVENUE

FIGURE 32 4D MOLECULAR THERAPEUTICS: REGIONAL REVENUE

FIGURE 33 SIRION BIOTECH GMBH: KEY FINANCIALS

FIGURE 34 SIRION BIOTECH GMBH: SEGMENTAL REVENUE

FIGURE 35 SIRION BIOTECH GMBH: REGIONAL REVENUE

FIGURE 36 VOYAGER THERAPEUTICS: KEY FINANCIALS

FIGURE 37 VOYAGER THERAPEUTICS: SEGMENTAL REVENUE

FIGURE 38 VOYAGER THERAPEUTICS: REGIONAL REVENUE

FIGURE 39 THERMO FISHER SCIENTIFIC, INC.: KEY FINANCIALS

FIGURE 40 THERMO FISHER SCIENTIFIC, INC.: SEGMENTAL REVENUE

FIGURE 41 THERMO FISHER SCIENTIFIC, INC.: REGIONAL REVENUE

FIGURE 42 GENE THERAPY CATAPULT: KEY FINANCIALS

FIGURE 43 GENE THERAPY CATAPULT: SEGMENTAL REVENUE

FIGURE 44 GENE THERAPY CATAPULT: REGIONAL REVENUE

FIGURE 45 UNIQURE: KEY FINANCIALS

FIGURE 46 UNIQURE: SEGMENTAL REVENUE

FIGURE 47 UNIQURE: REGIONAL REVENUE

FIGURE 48 MASSBIOLOGICS: KEY FINANCIALS

FIGURE 49 MASSBIOLOGICSSEGMENTAL REVENUE

FIGURE 50 MASSBIOLOGICS: REGIONAL REVENUE

FIGURE 51 RENOVA THERAPEUTICS: KEY FINANCIALS

FIGURE 52 RENOVA THERAPEUTICS: SEGMENTAL REVENUE

FIGURE 53 RENOVA THERAPEUTICS: REGIONAL REVENUE

FIGURE 54 SHENZHEN SIBIONO GENETECH CO., LTD: KEY FINANCIALS

FIGURE 55 SHENZHEN SIBIONO GENETECH CO., LTD: SEGMENTAL REVENUE

FIGURE 56 SHENZHEN SIBIONO GENETECH CO., LTD: REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.